Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer|Neoplasms|Breast Cancer
Interventions: DRUG: Trastuzumab (neoadjuvant)|DRUG: Pertuzumab (neoadjuvant)|DRUG: Paclitaxel (neoadjuvant)
Sponsor: Institut Català d'Oncologia
Collaborators: Instituto de Salud Carlos III|Fundación Sociedad Española de Oncologia Médica|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Reveal Genomics (Registered trademark)